POPULATION FEATURES OF THE GENETIC MARKER’S DISTRIBUTION OF THE HEART FAILURE EFFECTIVENESS THERAPY WITH SGLT2 INHIBITORS IN THE KAZAKH POPULATION
Various approaches to cardiovascular diseases and heart failure treatment are being considered and investigated. At present, researchers note the cardio protective effect of taking a new group of drugs ‒ SGLT2 inhibitors.
The purpose of the study: to conduct a comparative analysis of the population frequencies of alleles and genotypes of polymorphic variants of genes associated with the pharmacokinetics of dapaglifosine GWAS – SLC5A2 (rs9934336, rs3116150); PNPLA3 (rs738409); WFS1 (rs10010131); UGT2B4 (rs1080755), in an ethnically homogeneous population of Kazakhs with previously studied world populations.
A genomic database of 1800 healthy individuals of Kazakh nationality were used to analyse the population frequencies of alleles and genotypes of polymorphic variants of genes associated with the pharmacokinetics of dapagliflozin.
The results demonstrated that in the Kazakh population, the distribution of genotypes of the investigated gene polymorphisms associated with the effectiveness of heart failure therapy with SGLT2 inhibitors is in accordance with the Hardy-Weinberg equilibrium (p>0.05). High population frequencies of unfavourable alleles of gene polymorphisms were found ‒ PNPLA3 rs738409, which suggests their main genetic contribution to the prognosis of the effectiveness of therapy with SGLT2 inhibitors in the treatment of heart failure in the Kazakh population.
Based on the results of the GWAS analysis and meta-studies, 5 pan-ethnic polymorphisms were selected for further replicative genotyping of patients with heart failure treated with dapagliflozin to predict the efficacy and safety of therapy with SGLT2 inhibitors in the Kazakh population.
Number of Views: 154
Category of articles:
Original articles
Bibliography link
Svyatova G., Berezina G., Pashimov M., Mussagaliyeva A., Murtazaliyeva A., Danyarova L., Rakisheva A., Nurzhanova M. Population features of the genetic marker’s distribution of the heart failure effectiveness therapy with SGLT2 inhibitors in the Kazakh population // Nauka i Zdravookhranenie [Science & Healthcare]. 2023, (Vol.25) 4, pp. 49-58. doi 10.34689/SH.2023.25.4.006Related publications:
A COMPARATIVE ANALYSIS OF 24-HOUR DIETARY RECALLS AND FOOD FREQUENCY QUESTIONNAIRES ADMINISTERED SIMULTANEOUSLY IN THE KAZAKHSTANI POPULATION
ANALYSIS OF PATIENT SATISFACTION WITH THE QUALITY OF ORGANIZATION OF TREATMENT IN FOREIGN CLINICS
CLINICAL AND LABORATORY PREDICTORS OF THE SEVERITY OF COVID-19 INFECTION IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
POST-MARKETING STUDY OF THE CLINICAL EFFICACY AND SAFETY OF GRIPMAX NOS IN THE TREATMENT OF ACUTE RESPIRATORY INFECTIONS OF THE UPPER RESPIRATORY TRACT
EXPERIENCE IN IMPROVING SURGICAL TREATMENT WHEN IMPOSING A STOMA IN CHILDREN WITH HIRSPRUNG'S DISEASE